Aquestive Therapeutics, Inc. AQST Payments for Royalty Obligations
Payments for Royalty Obligations at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:PaymentsForRoyaltyObligations.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s payments for royalty obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s payments for royalty obligations?
- Aquestive Therapeutics, Inc. (AQST) reported payments for royalty obligations of $0 in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s payments for royalty obligations changed year-over-year?
- Aquestive Therapeutics, Inc.'s payments for royalty obligations decreased by 100.0% year-over-year, from $5K to $0.
- What does payments for royalty obligations mean?
- Represents cash outflows made to satisfy contractual royalty obligations related to licensed intellectual property or product rights. Monitoring these payments is essential for understanding the long-term cost structure and the impact of licensing agreements on net cash flow.